Skip to main content
. 2022 Apr 13;13:886225. doi: 10.3389/fimmu.2022.886225

Table 1.

Effect of IDO1 and IDO2 on autoimmune and inflammatory disease.

Disease Model(s) IDO1 ko IDO2 ko Inhibitors
Arthritis KRN no effect (13, 14) reduced (11, 13, 14) reduced
(18, 24, 61)
CIA Increased (22) n.d. reduced (24, 26)
increased (22, 23)
no effect (24, 25)
JIA no effect (20) n.d. n.d.
Psoriasis IMQ no effect (32) increased (32) n.d.
Multiple Sclerosis EAE increased (27, 28) no effect (28) increased (29, 30)
reduced (31)
Lupus Nba2 no effect (33) n.d. no effect (33)
MRL/lpr n.d. n.d. reduced (34)
increased (19)
Allergy/Asthma CHS reduced (12) reduced (11, 12) n.d.
Ag-induced asthma reduced (37) n.d. n.d.
Immunization T Independent Type I increased (9)
no effect (14)
no effect (14) n.d.
T Independent Type II increased (9)
no effect (14)
reduced (14) n.d.
T Dependent no effect (9, 14) no effect (14) n.d.
Influenza PR8 increased CD8 (38)
no effect on Ab (14, 38)
reduced (14) n.d.
Endotoxic Shock LPS reduced (39) increased (40) n.d.
Aspergillosis A. fumigatus reduced (41) n.d. n.d.

The inflammatory response in the listed models is indicated as increased, reduced,neither increased nor decreased (no effect), or not determined (n.d.).